Stock 300497 JIANGXI FUSHINE PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jiangxi Fushine Pharmaceutical Co., Ltd.

Equities

300497

CNE1000024Z7

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 06/05/2024 BST 		5-day change 1st Jan Change
11.65 CNY +0.52% Intraday chart for Jiangxi Fushine Pharmaceutical Co., Ltd. +16.50% +24.47%
04-28 Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-28 Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,020 5,010 6,586 8,887 7,110 5,042
Enterprise Value (EV) 1 3,916 4,891 5,337 8,465 7,500 5,937
P/E ratio 20.6 x 18 x 20.7 x 181 x -50.8 x -25.3 x
Yield 1.1% 1.06% 1.4% - - -
Capitalization / Revenue 3.46 x 3.7 x 4.41 x 6.22 x 4.32 x 3.13 x
EV / Revenue 3.37 x 3.61 x 3.57 x 5.92 x 4.55 x 3.69 x
EV / EBITDA 12.9 x 10.8 x 11.6 x 31.2 x 116 x 216 x
EV / FCF -74.1 x -34.3 x -84 x -17.2 x -14 x -17.6 x
FCF Yield -1.35% -2.91% -1.19% -5.8% -7.16% -5.67%
Price to Book 3.6 x 3.39 x 2.57 x 3.08 x 2.65 x 2.03 x
Nbr of stocks (in thousands) 425,070 424,769 461,535 544,206 538,649 538,649
Reference price 2 9.458 11.79 14.27 16.33 13.20 9.360
Announcement Date 28/04/19 08/04/20 23/04/21 28/04/22 25/04/23 28/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,163 1,354 1,493 1,430 1,647 1,610
EBITDA 1 302.9 451.4 458.1 271.3 64.41 27.51
EBIT 1 250.4 385.2 384.5 173.1 -59 -131.9
Operating Margin 21.52% 28.45% 25.75% 12.11% -3.58% -8.2%
Earnings before Tax (EBT) 1 227.1 358.4 378.8 55.07 -142.7 -233.2
Net income 1 194.7 305.8 319.3 48.83 -141.5 -200.8
Net margin 16.74% 22.59% 21.39% 3.42% -8.59% -12.47%
EPS 2 0.4583 0.6563 0.6900 0.0900 -0.2600 -0.3700
Free Cash Flow 1 -52.83 -142.5 -63.52 -490.8 -536.8 -336.8
FCF margin -4.54% -10.52% -4.25% -34.33% -32.59% -20.92%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.1042 0.1250 0.2000 - - -
Announcement Date 28/04/19 08/04/20 23/04/21 28/04/22 25/04/23 28/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 390 895
Net Cash position 1 104 118 1,249 422 - -
Leverage (Debt/EBITDA) - - - - 6.055 x 32.54 x
Free Cash Flow 1 -52.8 -142 -63.5 -491 -537 -337
ROE (net income / shareholders' equity) 18.2% 23% 14.1% 1.33% -5.86% -8.65%
ROA (Net income/ Total Assets) 7.85% 10% 7.24% 2.48% -0.76% -1.67%
Assets 1 2,480 3,044 4,412 1,969 18,681 12,028
Book Value Per Share 2 2.630 3.480 5.560 5.300 4.980 4.620
Cash Flow per Share 2 1.840 1.850 2.930 2.340 1.820 1.360
Capex 1 164 325 449 680 459 242
Capex / Sales 14.09% 23.99% 30.09% 47.54% 27.89% 15.05%
Announcement Date 28/04/19 08/04/20 23/04/21 28/04/22 25/04/23 28/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
JIANGXI FUSHINE PHARMACEUTICAL CO., LTD. Stock Jiangxi Fushine Pharmaceutical Co., Ltd.
+24.47% 866M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.43% 690B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.43% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.12% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.59% 323B
ABBVIE INC. Stock AbbVie Inc.
+4.89% 287B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.32% 235B
NOVARTIS AG Stock Novartis AG
+5.79% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.49% 195B
AMGEN INC. Stock Amgen Inc.
+4.26% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300497 Stock
  4. Financials Jiangxi Fushine Pharmaceutical Co., Ltd.